Vyleesi Alcohol Interaction Profile: What Patients and Clinicians Need to Know

What the FDA Label Says About Alcohol and Bremelanotide

The Vyleesi prescribing information does not list alcohol as a formal contraindication or a named drug interaction. The interaction section of the label covers two categories: drugs that affect melanocortin receptors and drugs that are substrates of specific CYP enzymes affected by bremelanotide's inhibitory activity at CYP1A2 and CYP3A4. Alcohol does not fall cleanly into either category at standard drink volumes. [1]

Why the Label Is Silent on Alcohol

Bremelanotide acts primarily on melanocortin receptors, not on alcohol-metabolizing enzymes (alcohol dehydrogenase, aldehyde dehydrogenase, or CYP2E1). Pre-marketing pharmacokinetic studies submitted to the FDA did not include a dedicated ethanol interaction study. This is common for on-demand sexual medicine drugs: the clinical trial population abstained or limited alcohol on dosing days, so the absence of a label warning reflects study design, not verified safety.

The FDA's Center for Drug Evaluation and Research (CDER) guidance on drug interaction studies notes that dedicated alcohol interaction studies are required primarily when a drug causes CNS depression or substantially inhibits the enzymes that metabolize ethanol. [2] Bremelanotide does not meet either criterion.

What the Approval Trials Recorded

The Phase 3 RECONNECT trials, which enrolled 1,267 premenopausal women with HSDD across two identical randomized controlled trials (Study 1 and Study 2), did not systematically capture alcohol co-use as a variable in the safety analysis. [3] Both studies excluded women with a current alcohol or substance use disorder, but social or moderate drinking was not an exclusion criterion. The pooled adverse event data therefore captures some real-world co-exposure without labeling it.

Pharmacodynamic Overlap: Where the Real Risk Lives

Even without a pharmacokinetic clash, the two substances share three overlapping biological effects that compound one another.

Nausea and Vomiting

Nausea is the dominant adverse event with bremelanotide. In the RECONNECT pooled safety population, 40% of women who received at least one 1.75 mg dose reported nausea, compared with 1% in the placebo arm. [3] Vomiting occurred in 4% of the active group. The nausea onset is typically within 30 minutes of injection and peaks within one hour.

Alcohol stimulates gastric acid secretion and activates the area postrema (the brain's chemoreceptor trigger zone) through multiple pathways, including acetaldehyde accumulation and vagal afferent signaling. [4] When a woman injects bremelanotide after two or more standard drinks, she simultaneously loads two separate emetic triggers. The additive nausea burden is a clinically meaningful concern, even if no controlled crossover study has quantified it formally.

The FDA-approved prescribing information for bremelanotide states: "The most common adverse reaction was nausea which occurred in 40% of women treated with bremelanotide." Pre-injection antiemetics (ondansetron 4 mg orally 30 minutes prior) are sometimes recommended off-label by prescribers for patients with a history of severe nausea on the drug. [1]

Transient Blood Pressure Changes

Bremelanotide produces a transient, dose-dependent increase in blood pressure that peaks within 12 minutes of injection and resolves within 12 hours. In Phase 3 trials, the maximum mean increase was approximately 2 mmHg systolic and 1 mmHg diastolic, but individual responses varied substantially. [1] For this reason, bremelanotide is contraindicated in women with uncontrolled hypertension or cardiovascular disease.

Alcohol's effect on blood pressure is biphasic. A single dose (roughly 1.0 g/kg) initially causes vasodilation and a modest blood pressure decrease, which is followed hours later by a rebound increase. [5] In a woman who drinks while bremelanotide's vasopressor phase is active, the net hemodynamic result is unpredictable: the alcohol-induced vasodilation may partially blunt the drug's pressor effect, or the rebound hypertension that follows alcohol metabolism may compound it later in the evening. Patients with borderline blood pressure should be counseled specifically about this timing issue.

CNS Sedation and Coordination

Bremelanotide's melanocortin receptor activity does not produce clinically significant sedation at the approved 1.75 mg dose. However, some women report mild dizziness or fatigue, reported in 2% of the RECONNECT population. [3] Alcohol is a CNS depressant, and even 1 to 2 standard drinks can impair coordination and increase fall risk. The combination could modestly amplify dizziness.

Pharmacokinetic Profile: Why Alcohol Does Not Alter Bremelanotide Exposure

Understanding why there is no pharmacokinetic interaction requires a brief review of how bremelanotide is processed.

Absorption and Distribution

Bremelanotide is administered subcutaneously. Following injection, absolute bioavailability is approximately 100%, with peak plasma concentration (Cmax) reached in 1 hour. The volume of distribution is 40 L, indicating moderate tissue distribution. [1] Alcohol does not alter subcutaneous absorption rates of peptide-based drugs at the injection site.

Metabolism

Bremelanotide is metabolized primarily by hydrolysis of amide bonds, not by hepatic CYP enzymes. [1] This is the single most important pharmacokinetic fact for the alcohol interaction question. Because CYP2E1 (the enzyme most responsible for ethanol oxidation at moderate alcohol concentrations) does not substantially contribute to bremelanotide clearance, competitive inhibition or induction by alcohol is not a mechanism of concern. Alcohol does not slow or accelerate bremelanotide clearance in any clinically meaningful way.

CYP Inhibition by Bremelanotide

Bremelanotide inhibits CYP1A2 and CYP3A4 in vitro. [1] Neither enzyme is the primary pathway for ethanol metabolism. CYP2E1 handles the majority of ethanol oxidation at social drinking doses, with CYP1A2 contributing only at very high blood alcohol concentrations (above 100 mg/dL). At the doses of bremelanotide used clinically, and at the blood alcohol levels produced by 1 to 3 standard drinks, any CYP1A2-mediated slowing of ethanol clearance is pharmacologically negligible.

A Clinical Decision Framework for Alcohol Use on Dosing Days

Given the lack of a formal contraindication and the real-world likelihood that women will consume alcohol on evenings when they intend to use bremelanotide, a structured clinical framework is more useful than a blanket prohibition.

Tier 1: Low-risk co-use (1 standard drink, consumed more than 1 hour before injection) One standard drink (14 g of ethanol) is unlikely to produce meaningful blood alcohol elevation at the time of bremelanotide's hemodynamic peak. The emetic risk is low but still additive. Most patients without prior severe nausea to the drug can proceed without dose modification.

Tier 2: Moderate-risk co-use (2 standard drinks, or 1 drink within 1 hour of injection) At 2 standard drinks, blood alcohol concentration in a 60-kg woman may reach 40 to 60 mg/dL. Nausea risk compounds significantly. Clinicians should discuss prophylactic antiemetic use and remind patients that vomiting in the 45-minute window before sexual activity may require rescheduling the dose. Blood pressure monitoring is advisable for patients with pre-hypertension.

Tier 3: High-risk co-use (3 or more standard drinks, or any amount in women with CVHD risk factors) Heavy drinking on a dosing day is inadvisable. The combination of MC4R-mediated nausea, alcohol-induced emesis pathways, and unpredictable hemodynamic overlap in a woman with cardiovascular risk creates an unacceptable side-effect profile. The bremelanotide dose should be deferred.

Patients with a history of GERD, gastroparesis, or prior chemotherapy-induced nausea are at higher baseline emetic risk and should be counseled at Tier 2 restrictions even if planning only 1 drink.

Drug Interactions Beyond Alcohol: What Else Bremelanotide Affects

Because patients may ask about the broader interaction profile in the context of a wine-and-medication conversation, the following summary is clinically relevant.

Naltrexone

The prescribing information specifically warns that bremelanotide may reduce the rate (but not the extent) of absorption of oral naltrexone, likely through delayed gastric emptying mediated by the drug's effect on GI motility. [1] Women in medication-assisted treatment for alcohol use disorder who are taking oral naltrexone 50 mg daily should discuss this interaction with their prescriber before using bremelanotide. The interaction is not a hard contraindication, but timing naltrexone administration to a morning dose (rather than the evening of bremelanotide use) is reasonable.

Other Orally Administered Drugs

By the same GI motility mechanism, bremelanotide may delay the absorption of other oral medications taken within 2 to 4 hours of injection. This includes oral contraceptives, which some women take at a consistent daily time. The label advises that women using oral hormonal contraception take the dose at least 1 hour before bremelanotide injection. [1]

Antihypertensives

Women on antihypertensive therapy were excluded from RECONNECT. Co-administration with antihypertensives is not formally studied. Given bremelanotide's pressor effect, prescribers should use clinical judgment and may consider blood pressure monitoring for the first few doses if antihypertensive co-use is unavoidable. [1]

What Happens If a Patient Uses Bremelanotide With Alcohol and Experiences Severe Nausea

In clinical trials, women who developed grade 2 or higher nausea (defined as nausea interfering with normal activities) had their dose withheld until the episode resolved. The label does not provide rescue medication guidance, but the following clinical sequence is standard practice:

1. Position the patient to avoid aspiration if vomiting is severe.
2. Oral rehydration with clear fluids when tolerated.
3. Ondansetron 4 to 8 mg orally or sublingually if nausea persists beyond 2 hours.
4. Blood pressure check if the patient is symptomatic (lightheadedness, palpitations).
5. Defer the next bremelanotide dose by at least 24 hours.

If the patient required emergency care for hemodynamic instability or uncontrolled vomiting, the prescribing clinician should document the event, rule out concurrent cardiovascular disease, and reassess the risk-benefit ratio of continuing therapy.

Special Populations: Premenopausal Women and Alcohol Pharmacokinetics

Bremelanotide is approved only for premenopausal women with HSDD. This population matters for alcohol pharmacokinetics because body composition and hormonal status influence ethanol distribution.

Premenopausal women have higher body fat percentage relative to total body water compared with men of similar weight, producing higher peak blood alcohol concentrations per gram of ethanol consumed. [6] A woman weighing 65 kg who consumes 2 standard drinks may reach a blood alcohol concentration 20 to 30% higher than a 65-kg man consuming the same drinks over the same interval.

The practical implication: the 1-drink Tier 1 threshold in the framework above is calibrated to the premenopausal female body water average. Women with lower body weight (<55 kg) or those who report subjective alcohol sensitivity should lower their threshold to 0.5 standard drinks on dosing days.

Patient Counseling Talking Points

The Endocrine Society's 2019 clinical practice guidelines on female sexual dysfunction note that HSDD treatment decisions should be individualized and account for lifestyle factors, including alcohol use. [7] A consistent counseling framework builds trust and reduces the likelihood of patients self-experimenting without guidance.

Clinicians should cover four points at the time of prescription:

Point 1. Bremelanotide does not interact with alcohol at the pharmacokinetic level. The drug is broken down by amide hydrolysis, not by liver enzymes that alcohol affects.

Point 2. Nausea is common on the drug alone. Drinking before or around the time of injection makes nausea more likely and more severe.

Point 3. Bremelanotide raises blood pressure briefly. Alcohol's effect on blood pressure adds uncertainty, especially for patients who already have borderline readings.

Point 4. If patients plan to have 1 to 2 drinks on an evening they intend to use the drug, they should eat a full meal first, finish drinking at least 1 hour before injection, and keep ondansetron on hand.

The North American Menopause Society (NAMS) position statement on HSDD pharmacotherapy, updated in 2022, states: "Clinicians prescribing bremelanotide should provide anticipatory guidance regarding nausea management, as this is the side effect most likely to lead to discontinuation." [8]

Monitoring and Follow-Up Recommendations

No specific monitoring protocol is mandated by the label beyond blood pressure measurement before prescribing for patients with borderline hypertension. Across the RECONNECT trials, 1.7% of women discontinued bremelanotide due to nausea. [3] In clinical practice, the discontinuation rate for nausea may be higher, particularly when co-use with alcohol is not counseled against.

A follow-up contact at 30 days post-prescription is reasonable. At that visit, clinicians should ask:

• How many doses has the patient used?
• Did nausea occur? Was it manageable?
• Was alcohol consumed on any dosing day? What amount?
• Were there any blood pressure symptoms (headache, pounding heartbeat)?

Women reporting nausea on 2 or more doses should be offered a prophylactic antiemetic protocol before the next use. Women reporting both alcohol co-use and nausea should be guided to the Tier 1 or Tier 2 framework above and asked to try the drug on an alcohol-free evening as a controlled self-experiment.

Blood pressure should be remeasured in any patient who reports new-onset headache, visual changes, or palpitations after a dose, particularly if alcohol was also consumed that evening.